suramin has been researched along with Hypertension, Pulmonary in 3 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Suramin treatment suppressed PA-SMC proliferation and attenuated both the inflammatory response and the deposition of collagen." | 5.39 | The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. ( Dartevelle, P; Dorfmüller, P; Eddahibi, S; Fadel, E; Guin, LL; Hoang, E; Humbert, M; Izikki, M; Lecerf, F; Mercier, O; Perros, F; Simonneau, G, 2013) |
| " Suramin, an inhibitor of growth factor receptor binding inhibits the development of chronic hypoxic pulmonary hypertension in rats." | 3.69 | Vascular endothelial growth factor in pulmonary hypertension. ( Hoeper, M; Maloney, J; Tuder, RM; Voelkel, NF, 1996) |
| "Suramin treatment suppressed PA-SMC proliferation and attenuated both the inflammatory response and the deposition of collagen." | 1.39 | The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats. ( Dartevelle, P; Dorfmüller, P; Eddahibi, S; Fadel, E; Guin, LL; Hoang, E; Humbert, M; Izikki, M; Lecerf, F; Mercier, O; Perros, F; Simonneau, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Izikki, M | 1 |
| Mercier, O | 1 |
| Lecerf, F | 1 |
| Guin, LL | 1 |
| Hoang, E | 1 |
| Dorfmüller, P | 1 |
| Perros, F | 1 |
| Humbert, M | 1 |
| Simonneau, G | 1 |
| Dartevelle, P | 1 |
| Fadel, E | 1 |
| Eddahibi, S | 1 |
| Visovatti, SH | 1 |
| Hyman, MC | 1 |
| Goonewardena, SN | 1 |
| Anyanwu, AC | 1 |
| Kanthi, Y | 1 |
| Robichaud, P | 1 |
| Wang, J | 1 |
| Petrovic-Djergovic, D | 1 |
| Rattan, R | 1 |
| Burant, CF | 1 |
| Pinsky, DJ | 1 |
| Voelkel, NF | 1 |
| Hoeper, M | 1 |
| Maloney, J | 1 |
| Tuder, RM | 1 |
3 other studies available for suramin and Hypertension, Pulmonary
| Article | Year |
|---|---|
The beneficial effect of suramin on monocrotaline-induced pulmonary hypertension in rats.
Topics: Animals; Apoptosis; Cell Proliferation; Enzyme Activation; Humans; Hypertension, Pulmonary; In Vitro | 2013 |
Purinergic dysregulation in pulmonary hypertension.
Topics: Adenosine; Adenosine Triphosphate; Animals; Antigens, CD; Antihypertensive Agents; Apyrase; Arterial | 2016 |
Vascular endothelial growth factor in pulmonary hypertension.
Topics: Animals; Blotting, Northern; Cell Line; Endothelial Growth Factors; Humans; Hypertension, Pulmonary; | 1996 |